The case for & against
Bull & Bear analysis
Bearish
Lantern Pharma, Inc. (NASDAQ: LTRN) is an innovative biotechnology company focused on precision oncology, using artificial intelligence (AI) and machine learning to develop targeted therapies for oncology with a particular emphasis on cancers with limited treatment options. The company leverages its proprietary RADAR AI platform to enhance efficiency in drug discovery and optimize clinical trial execution.
Bull says
- ↑86% clinical benefit rate in LP-300 Phase 2 non-small cell lung cancer trial
- ↑$24M cash runway through mid-2026 supports R&D and operations
- ↑Multiple FDA fast-track and orphan designations for LP-300 and LP-184
- ↑RADAR AI platform leverages 200B oncology data points to speed drug discovery
- ↑Asia trial sites enroll 2–4× faster, potentially accelerating readouts
- ↑Strong liquidity and favorable short interest indicate investor confidence
Bear says
- ↓$20.8M net loss in 2024, requiring substantial new capital soon
- ↓R&D spend climbed to $16.1M with no imminent revenue offset
- ↓Slow market uptake risk for niche non-small cell lung cancer therapy
- ↓Intense competition from MRTX, ZYME, MRNA, and GILD in oncology
- ↓Negative earnings yield and poor profitability factors signal return risk
- ↓Elevated leverage and high short interest heighten share volatility
Investment themes with LTRN
Biotech↑ +1.37%
Genetic and drug innovations driving medical breakthroughs
ABBV · TMO · AMGN
Most Shorted Stocks↑ +0.88%
Stocks with highest short interest
LITE · AXTI · NVTS
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 06-30-2026bullish
Transcript signals
Bull points
- We anticipate this balance will provide us with a cash runway into at least late 2025.
- Importantly, we believe our solid financial position will fuel continued growth and evolution of our RadarAR platform, continue the development of our portfolio of targeted oncology drug candidates, and allow us to introduce additional targeted programs and collaboration opportunities efficiently and effectively.
- Many of the initial observations made with the help of Radar are now being brought forth into the clinic, as you can see in our portfolio slide that's being presented.
Bear points
- We recorded a net loss of approximately $4.5 million for the third quarter of 2024 or 42 cents per share compared to a net loss of approximately $3.2 million or 29 cents per share for the third quarter of 2023.
- our R&D expenses were approximately $3.7 million or up from approximately $2.2 million for the third quarter of 2023. This increase was largely driven by an increase in clinical trial activity.
- Our general and administrative expenses for the third quarter of 2024 were approximately $1.5 million, up slightly from approximately $1.3 million for the third quarter of 2023. The increase was primarily attributable to increases in professional fees and increased patent and legal fees.
Read full transcript analysis ›